Details of the Drug Combination

General Information of Drug Combination (ID: DCMOQG0)

Drug Combination Name
Leuprolide Pyrotinib
Indication
Disease Entry Status REF
Acute HIV Infection Phase 1 [1]
Component Drugs Leuprolide   DM5XPIJ Pyrotinib   DMW7K39
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Leuprolide
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [2]
Prostate cancer 2C82.0 Approved [3]
Endometriosis GA10 Investigative [2]
Leuprolide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [5]
------------------------------------------------------------------------------------
Leuprolide Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Increases ADR [6]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Increases ADR [6]
Protein bric-a-brac 2 (bab2) OTNNK0KI BAB2_DROME Increases ADR [6]
------------------------------------------------------------------------------------
Indication(s) of Pyrotinib
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Pyrotinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
EGFR messenger RNA (EGFR mRNA) TTG96HZ EGFR_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05087706) Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland CancerMAPS?Unknown status
2 Leuprolide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.